Positron emission tomography using 18f-fluorodeoxyglucose in advanced stages of malignant melanoma a comparison of ultrasonographic and radiological methods of diagnosis

Nuclear Medicine Communications

Volumn 20, Issue 3, 1999, Pages 255-262

  Dietlein, M ^a   Smolarz, K ^a   Scheidhauer, K ^a   Schicha, H ^a   Krug, B ^a   Psaras, T ^a   Lackner, K ^a   StuTzer H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; BONE METASTASIS; CANCER SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS;

ADOLESCENT; ADULT; BONE NEOPLASMS; BRAIN NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0032960959     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199903000-00008     Document Type: Article

References (15)

1. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography: A comparative retrospective study assessing the diagnostic validity in lymph node métastasés of malignant melanoma. Arch Dermatol 1995; 131: 1394-1398.
2. Böni R, Huch Boni RA, Steinert H et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995; 132: 556-562.
3. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6: 325-329.
4. Deutsche Gesellschaft für Nuklearmedizin: Nachrichten: Konsensus-Onko-PET. Nuklearmedizin 1997; 36: 45-46.
5. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body fluorodeoxyglucose accumulations. J Nucl Med 1996; 37: 441-446.
6. Ghanem G, Loir B, Pector JC et al. Evaluation of serum protein S-100 as a new melanoma marker: Validation in isolated limb perfusion with tumour necrosis factor. Melanoma Res 1996; 6(1): S50.
7. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34: 1425-1427.
8. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmüller D. Clinical significance of serum S 100 in metastatic malignant melanoma. Eur J Cancer 1995; 31A: 924-928.
9. Krähn G, Kaskel P, Rust A, Peter U. Serum-S 100 bei meta-stierendem Melanom. Münch Med Wschr 1998; 140: 326-327.
10. Schoultz von E, Hansson LO, Djureen E et al. Prognostic value of serum analyses of S-100ß protein in malignant melanoma. Melanoma Res 1996; 6: 133-137.
11. Pounds TR, Valk PE, Hasemann MK, Myers RW, Lutrin CL. Whole-body PET-FDG imaging in diagnosis of metastatic melanoma: Comparison to CT. J Nucl Med 1995; 36: 116P.
12. Reske SN. Positronen-Emissions-Tomographie in der Onkologie. Deutsches Ärzteblatt 1998; 95: C1370-1372.
13. Reske SN, Bares R, Büll U, Guhlmann A, Moser E, Wannen-macher MF. Klinische Wertigkeit der Positronen-Emissions-Tomographie (PET) bei onkologischen Fragestellungen: Ergebnisse einer interdisziplinären Konsensuskonferenz. Nuklearmedizin 1996; 35: 42-52.
14. Steinert HC, Huch Böni RA, Buck A et al. Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195: 705-709.
15. Steinert HC, Ullrich SP, Böni R, von Schulthess GK, Dummer R. Kosteneffektivität beim Staging des malignen Melanoms: Vergleich Ganzkörper PET versus kon ventionelles Staging. Nuklearmedizin 1998; 37: A37.